drugset / Trial / NCT00162929
Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)
Phase 1
Completed
5 enrolled
Ontario Clinical Oncology Group (OCOG)
Canadian Breast Cancer Research Alliance · collabOntario Cancer Research Network · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of human autologous dendritic cells transduced by an adenovector expressing rat Her-2/neu (AdHer-2/neu) in patients with metastatic breast cancer.
Timeline
- Start
- 2005-01
- Primary completion
- 2009-07
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AdHer-2/neu transduced dendritic cells | Cell therapy | 1e+07 cells | — |
| Subject | AdHer-2/neu transduced dendritic cells | Cell therapy | 5e+07 cells | — |
| Subject | AdHer-2/neu transduced dendritic cells | Cell therapy | 1e+08 cells | — |